User:Mr. Ibrahem/Valsartan
Clinical data | |
---|---|
Trade names | Diovan, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a697015 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Angiotensin II receptor antagonist |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 25% |
Protein binding | 95% |
Elimination half-life | 6 hours |
Excretion | Kidney 30%, biliary 70% |
Identifiers | |
| |
Chemical and physical data | |
Formula | C24H29N5O3 |
Molar mass | 435.528 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Valsartan, sold under the trade name Diovan among others, is a medication used to treat high blood pressure, heart failure, and diabetic kidney disease.[4] It is a reasonable initial treatment for high blood pressure.[4] It is taken by mouth.[4] Versions are available as the combination valsartan/hydrochlorothiazide, valsartan/amlodipine, valsartan/amlodipine/hydrochlorothiazide, or valsartan/sacubitril.[4][5]
Common side effects include feeling tired, dizziness, high blood potassium, diarrhea, and joint pain.[4] Other serious side effects may include kidney problems, low blood pressure, and angioedema.[4] Use in pregnancy may harm the baby and use when breastfeeding is not recommended.[6] It is an angiotensin II receptor antagonist and works by blocking the effects of angiotensin II.[4]
Valsartan was patented in 1990, and came into medical use in 1996.[7] It is available as a generic medication.[8] A month supply in the United Kingdom costs the NHS about 5 £ per month as of 2019.[8] In the United States the wholesale cost of this amount is about US$7.50.[9] In 2017, it was the 85th most commonly prescribed medication in the United States, with more than nine million prescriptions.[10][11]
References[edit]
- ^ a b "Valsartan Use During Pregnancy". Drugs.com. 28 March 2019. Archived from the original on 20 April 2020. Retrieved 12 February 2020.
- ^ "Valsartan 160 mg capsules - Summary of Product Characteristics (SmPC)". (emc). 19 February 2019. Archived from the original on 13 February 2020. Retrieved 12 February 2020.
- ^ "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 1 December 2020. Retrieved 6 September 2020.
- ^ a b c d e f g "Valsartan Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
- ^ "Sacubitril and Valsartan Monograph for Professionals". Drugs.com. 7 November 2019. Archived from the original on 4 January 2020. Retrieved 12 February 2020.
- ^ "Valsartan Pregnancy and Breastfeeding Warnings". Drugs.com. Archived from the original on 20 April 2020. Retrieved 3 March 2019.
- ^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 470. ISBN 9783527607495. Archived from the original on 12 June 2020. Retrieved 1 March 2019.
- ^ a b British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 179. ISBN 9780857113382.
- ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
- ^ "The Top 300 of 2020". ClinCalc. Archived from the original on 18 March 2020. Retrieved 11 April 2020.
- ^ "Valsartan - Drug Usage Statistics". ClinCalc. Archived from the original on 11 April 2020. Retrieved 11 April 2020.